Betta Pharmaceutical announced that the company's application for clinical trials of injectable BPI-585771 intended to treat advanced solid tumors has been accepted by the State Drug Administration. The acceptance number is CXHL2601308. The drug is a novel PROTAC degrading agent independently developed by the company that targets various KRAS mutants. It can simultaneously combine activated and inactivated KRAS to induce ubiquitination and proteasomal degradation, inhibit downstream signaling pathways and induce apoptosis of tumor cells. Currently, many KRASPROTAC degrading agents are in the clinical development stage, and this drug will not have a significant impact on the company's revenue in the short term.

Betta Pharmaceutical announced that the company's application for clinical trials of injectable BPI-585771 intended to treat advanced solid tumors has been accepted by the State Drug Administration. The acceptance number is CXHL2601308. The drug is a novel PROTAC degrading agent independently developed by the company that targets various KRAS mutants. It can simultaneously combine activated and inactivated KRAS to induce ubiquitination and proteasomal degradation, inhibit downstream signaling pathways and induce apoptosis of tumor cells. Currently, many KRASPROTAC degrading agents are in the clinical development stage, and this drug will not have a significant impact on the company's revenue in the short term.